



Lowe, S. A., Usowicz, M. M., & Hodge, J. J. L. (2019). Neuronal overexpression of Alzheimer's disease and down's syndrome associated DYRK1A/minibrain gene alters motor decline, neurodegeneration and synaptic plasticity in *Drosophila*. *Neurobiology of Disease*, 125, 107-114. <https://doi.org/10.1016/j.nbd.2019.01.017>

Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1016/j.nbd.2019.01.017](https://doi.org/10.1016/j.nbd.2019.01.017)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://www.sciencedirect.com/science/article/pii/S0969996118303334>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

1 **Neuronal overexpression of Alzheimer's disease and Down's syndrome associated**
2 ***DYRK1A/minibrain* gene alters motor decline, neurodegeneration and synaptic**
3 **plasticity in *Drosophila***

4

5

6

7 *Simon A Lowe, Maria M Usowicz* and James JL Hodge**

8

9 School of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk,
10 Bristol BS8 1TD, UK

11

12 *corresponding authors: Drs Maria Usowicz (m.m.usowicz@bristol.ac.uk) and James Hodge
13 (james.hodge@bristol.ac.uk)

14

15

16 Keywords: Down's syndrome, Alzheimer's disease, *DYRK1A/minibrain*, *Drosophila*,
17 neuromuscular junction, synaptic transmission, neurodegeneration, motor decline, short-term
18 synaptic depression, spontaneous vesicular transmitter release

19

20 **Abstract**

21 Down syndrome (DS) is characterised by abnormal cognitive and motor development, and
22 later in life by progressive Alzheimer's disease (AD)-like dementia, neuropathology, declining
23 motor function and shorter life expectancy. It is caused by trisomy of chromosome 21 (Hsa21),
24 but how individual Hsa21 genes contribute to various aspects of the disorder is incompletely
25 understood. Previous work has demonstrated a role for triplication of the Hsa21 gene *DYRK1A*
26 in cognitive and motor deficits, as well as in altered neurogenesis and neurofibrillary
27 degeneration in the DS brain, but its contribution to other DS phenotypes is unclear. Here we
28 demonstrate that overexpression of *minibrain (mnb)*, the *Drosophila* ortholog of *DYRK1A*, in
29 the *Drosophila* nervous system accelerated age-dependent decline in motor performance and
30 shortened lifespan. Overexpression of *mnb* in the eye was neurotoxic and overexpression in
31 ellipsoid body neurons in the brain caused age-dependent neurodegeneration. At the larval
32 neuromuscular junction, an established model for mammalian central glutamatergic synapses,
33 neuronal *mnb* overexpression enhanced spontaneous vesicular transmitter release. It also
34 slowed recovery from short-term depression of evoked transmitter release induced by high-
35 frequency nerve stimulation and increased the number of boutons in one of the two
36 glutamatergic motor neurons innervating the muscle. These results provide further insight into
37 the roles of *DYRK1A* triplication in abnormal aging and synaptic dysfunction in DS.

39 **Highlights**

- 40 • Overexpression of *minibrain* (*DYRK1A*) causes Down's relevant phenotypes including:
- 41 • Age-dependent degeneration of brain neurons
- 42 • Accelerated age-dependent decline in motor performance and shorted lifespan
- 43 • Modified presynaptic structure and enhanced spontaneous transmitter release
- 44 • Slowed recovery from short-term depression of synaptic transmission

45

46 **Acknowledgments**

47 We thank Dr Scott Waddell (University of Oxford) for *Canton Special white-* (CSw-) flies, Dr
48 Kweon Yu (Korea Research Institute of Bioscience and Biotechnology) for *UAS-mnb* flies
49 (*minibrain-H*, CG42273) and Dr Frank Hirth (Kings College London) for *EB1-Gal4; UAS-*
50 *mCD8-GFP* flies.

51

52 **Funding**

53 This work was supported by a BBSRC DTP (Doctoral Training Partnership) studentship.

54

55 **Introduction**

56 Down syndrome (DS, also known as Down's syndrome) or trisomy 21 is caused by the
57 presence of three copies of chromosome 21 (Hsa21) instead of the usual two (Herault et al.,
58 2017). It is characterised by cognitive impairment (Lott and Dierssen, 2010) and the delayed
59 and incomplete acquisition of motor skills (Malak et al., 2015) as a result of abnormal
60 development of the nervous system (Stagni et al., 2018). Individuals with DS almost invariably
61 develop Alzheimer's disease (AD)-like symptoms (AD-DS). These include progressive
62 dementia after 40 years of age, the onset of amyloid plaques, neurofibrillary tangles (NFTs)
63 and neurodegeneration after 10 – 20 years (Wiseman et al., 2015; Zigman, 2013), faster age-
64 dependent motor decline that is an early marker for the onset of cognitive decline and health
65 deterioration (Anderson-Mooney et al., 2016; Buchman and Bennett, 2011), and a shorter

66 mean life expectancy by approximately 28 years (O'Leary et al., 2018). Currently there is no
67 treatment for DS or AD; our understanding of the mechanisms of the disorder is incomplete
68 and this hampers the development of effective therapies.

69

70 One of the Hsa21 genes, *DYRK1A* (dual specificity tyrosine-phosphorylation-regulated kinase
71 1A), is a candidate causative gene for the structural and functional changes that occur in the
72 DS brain, and for the associated cognitive and motor deficits (Herault et al., 2017; Stagni et
73 al., 2018). *DYRK1A/Dyrk1a* mRNA and protein are expressed throughout the brain in humans
74 and rodents, wherein *DYRK1A* controls aspects of neuronal development and function
75 (Duchon and Herault, 2016; Kay et al., 2016; Stringer et al., 2017). *DYRK1A/Dyrk1a* mRNA
76 and protein expression is increased in DS brain and in the brain of different mouse models of
77 DS (Duchon and Herault, 2016; Garcia-Cerro et al., 2018; Kay et al., 2016; Stringer et al.,
78 2017), whether the gene is triplicated as part of a genomic segment, as in Dp1Yey, Ts65Dn,
79 Ts1Cje and Tc1 mice, or alone as in TgDyrk1a and TgDYRK1A mice (Herault et al., 2017).

80

81 DS-associated cognitive and motor deficits are replicated by overexpression of *Dyr1ka* in mice
82 (Ahn et al., 2006; Altafaj et al., 2001; Altafaj et al., 2013; Arque et al., 2013; García-Cerro et
83 al., 2014; Garcia-Cerro et al., 2018; Martínez de Lagrán et al., 2004; Ortiz-Abalia et al., 2008;
84 Souchet et al., 2014; Watson-Scales et al., 2018). However, the contribution of *DYRK1A*
85 overexpression to the shorter life expectancy, faster age-dependent decline in cognitive and
86 motor function, and development of AD-like pathology in DS is unclear. It is predicted to play
87 a role as it both phosphorylates tau and alters its splicing (Shi et al., 2008; Woods et al., 2001),
88 promoting its self-aggregation (Liu et al., 2008) into NFTs. *Dyrk1A* is found physically
89 associated with NFTs in the brain to a greater level in DS-AD than non-DS associated AD
90 (Wegiel et al., 2008; Wegiel et al., 2011). In the Ts65Dn and Ts1Cje mouse models of DS,
91 *Dyrk1a* overexpression in the brain intensifies with age (Ahmed et al., 2017; Creau et al., 2016;
92 Stringer et al., 2017; Watson-Scales et al., 2018), and this is associated with AD-DS-like
93 histopathological changes in the aged Ts65Dn brain (García-Cerro et al., 2017; Wiseman et

94 al., 2015). However, there is insufficient behavioural data from aged animals to directly assess
95 the impact of *DYRK1A* overexpression in inducing DS-AD phenotypes.

96

97 Cognitive and motor dysfunction in individuals with DS and in mouse models of DS are
98 associated with changes in synaptic plasticity and with changes in the number and structure
99 of GABAergic and glutamatergic brain neurons and synapses (Battaglia et al., 2008;
100 Contestabile et al., 2017; Duchon and Herault, 2016). Such modifications have been linked to
101 *Dyrk1a* overexpression (Duchon and Herault, 2016; García-Cerro et al., 2017; Garcia-Cerro
102 et al., 2018; Ruiz-Mejias et al., 2016), but the effects of *Dyrk1a* overexpression on the basic
103 properties of synaptic function have rarely been explored. In one study, there was no change
104 in the frequency of miniature excitatory synaptic currents (mEPSCs) or the probability of
105 electrically-evoked glutamate release in the prefrontal cortex of TgDyrk1a mice (Thomazeau
106 et al., 2014). Nevertheless, since *Dyrk1a* controls the activity of proteins that regulate
107 endocytosis (Murakami et al., 2012) and *DYRK1A* overexpression slows endocytosis of
108 transmitter vesicles in hippocampal presynaptic membranes from TgDYRK1A mice (Kim et
109 al., 2010), modulation of transmitter release at other glutamatergic synapses is likely.

110

111 To investigate the contribution of *DYRK1A* overexpression in the nervous system to various
112 aspects of DS, we overexpressed *minibrain (mnb)*, the *Drosophila* ortholog of *DYRK1A*
113 (Duchon and Herault, 2016), in the *Drosophila* nervous system and implemented well-
114 established assays in larvae and adult flies (Bykhovskaia and Vasin, 2017; Lenz et al., 2013;
115 McGurk et al., 2015). The assays monitored motor impairment and its development with age,
116 lifespan, age-related neurodegeneration, and synaptic dysfunction. Due to their short lifecycle,
117 *Drosophila* are one of the pre-eminent models for aging and neurodegeneration (Jones and
118 Grotewiel, 2011), both aspects of DS that are more difficult to investigate in mice. The
119 *Drosophila* larval neuromuscular junction (NMJ) is a well-established model for mammalian
120 central glutamatergic synapses and is easily accessible to electrophysiology (Bykhovskaia

121 and Vasin, 2017). *Mnb* is expressed presynaptically at larval NMJs and reducing its expression
122 changes motor nerve terminal structure and impairs recycling of transmitter vesicles, while
123 overexpression of one isoform, *mnb-F*, has no effect on basal transmission but ameliorates
124 the effects of reduced *mnb* expression (Chen et al., 2014). Five *mnb* isoforms, *E-I*, have been
125 identified, all of which share a highly conserved kinase domain (Gramates et al., 2017; Hong
126 et al., 2012). Regions of DYRK1A outside the kinase domain also appear to play important
127 roles, but which areas exactly and how they impact function is thus far incompletely
128 understood (Jin et al., 2015; Kelly and Rahmani, 2005; von Groote-Bidlingmaier et al., 2003).
129 We therefore utilised *mnb-H*, the isoform with the longest coding region (Gramates et al., 2017;
130 Zerbino et al., 2018). Here we report the effects of neuronal overexpression of *mnb-H* on motor
131 function, the rate of motor decline with age, lifespan, age-related neurodegeneration,
132 presynaptic structure, spontaneous transmitter release and recovery from frequency-
133 dependent depression of electrically-evoked transmitter release.

134

135 **Results**

136

137 **Neuronal overexpression of *mnb* produced motor deficits in larvae, accelerated age-**
138 **dependent motor decline in adult flies and shortened adult lifespan**

139 The effect of *mnb* overexpression in the nervous system on motor function (specifically the
140 *mnb-H* splice variant) was tested using two assays of fly larval locomotion. *Elav>mnb* larvae,
141 overexpressing *mnb* throughout the nervous system under the control of the *Elav-Gal4* driver
142 (Robinow and White, 1991), did not move as far as control larvae (*Elav/+*) in a free movement
143 assay (Fig. 1A), which measures the ability of larvae to perform rhythmic muscle contractions
144 necessary for gross locomotion (Kohsaka et al., 2017). They also took longer to complete a
145 self-righting assay (Fig. 1B), which is a more complex motor task requiring larvae to enact a
146 co-ordinated sequence of movements to right themselves after being rolled onto their backs
147 (Picao-Osorio et al., 2015). To assess the impact of neuronal *mnb* overexpression on age-
148 related decline in locomotor function, the performance of the same cohorts of adult flies was
149 assessed in a negative geotaxis assay at different ages (Jones and Grotewiel, 2011). This
150 showed acceleration in *Elav>mnb* flies of the usual age-related decline in performance
151 (*Elav/+*). There was also evident shortening of the lifespan of *Elav>mnb* flies, so that the
152 median lifespan was reduced by almost 50% (*Elav/+*, 73 days; *Elav>mnb*, 38 days; Fig. 1D).
153 These results indicate that neuronal overexpression of *mnb* alone produced a motor deficit
154 and abnormal aging characterised by accelerated age-related locomotor impairment and a
155 shorter lifespan.

156

157 **Overexpression of *mnb* caused neurodegeneration in adult flies**

158 As *DYRK1A* triplication has been linked to degeneration of brain neurons in AD-DS and in
159 Ts65Dn mice (García-Cerro et al., 2017; Wegiel et al., 2008), we tested the possibility that
160 neuronal overexpression of *mnb* is sufficient to cause neurotoxicity and age-related
161 neurodegeneration using two established assays of neurodegeneration in adult flies (Lenz et
162 al., 2013; McGurk et al., 2015). In the first, *mnb* was overexpressed in the eye through

163 development and adulthood using the *Glass multimer reporter* driver (*GMR-Gal4*) (Ellis et al.,
164 1993). The *GMR>mnb* flies, but not control flies (*GMR/+*), had a reduced eye surface area
165 and a visible “rough eye” phenotype (Fig. 2A), both of which indicate neural death and the
166 resultant breakdown of the regularly spaced array of ommatidia making up the retina. In a
167 second assay, the *EB1* driver (*EB1-Gal4*) was used to overexpress *mnb* in the ellipsoid body
168 (EB), a subpopulation of neurons within the central complex of the brain implicated in
169 locomotor control (Fig. 2B) (Diaper et al., 2013). The EB cells also expressed membrane-
170 bound GFP which enabled their visualisation. At 1 day old, there was no difference in the
171 number of GFP-positive EB neurons between control (*EB1/+*) and *EB1>mnb* flies, whereas at
172 day 40 the number of EB neurons was significantly reduced in *EB1>mnb* flies but not in control
173 flies (Fig. 2C). Therefore, neurotoxicity caused by *mnb* overexpression promoted age-related
174 neurodegeneration in a central neuron population.

175

176 **Overexpression of *mnb* in motor neurons increased the number of synaptic boutons at** 177 **the larval NMJ**

178 To investigate the effect of *mnb* overexpression on presynaptic morphology, *mnb* was
179 overexpressed in glutamatergic motor neurons of *Drosophila* larvae using *OK371-Gal4* (Mahr
180 and Aberle, 2006). The neuronal membranes were labelled with horseradish peroxidase
181 (HRP). The muscle is innervated by two motor neurons with functionally and structurally
182 distinct presynaptic boutons; 1s (small) boutons have higher excitation thresholds, higher
183 basal probability of release and induce larger post-synaptic potentials, while short-term and
184 homeostatic plasticity are largely mediated by 1b (big) boutons (Atwood et al., 1997; Newman
185 et al., 2017). These were differentiated by the stronger postsynaptic expression of Discs large
186 (Dlg) opposite 1b boutons (Lahey et al., 1994) Analysis of the NMJ in the second abdominal
187 larval segment, A2, showed that *mnb* overexpression affected the morphology of the nerve
188 terminals of only one of the motor neurons; it increased the number of 1b boutons but did not
189 alter the number of 1s boutons (Fig. 3A-B). The effect was not secondary to changes in muscle

190 size, as this did not differ (surface area of muscle 6: *OK371/+*, $44752 \pm 1407 \mu\text{m}^2$, $n = 15$;
191 *OK371>mbn*, $44681 \pm 3684 \mu\text{m}^2$, $n = 15$, $P = 0.9857$).

192

193 **Overexpression of *mbn* in motor neurons altered basal synaptic transmission at the** 194 **larval NMJ**

195 As neuronal overexpression of *mbn* increased the number of 1b boutons at the larval NMJ,
196 and because previous studies have implicated *Dyrk1a/mbn* in the control of the recycling of
197 neurotransmitter vesicles (Chen et al., 2014; Kim et al., 2010; Murakami et al., 2012), we
198 investigated if spontaneous glutamate release was altered by recording spontaneously
199 occurring miniature excitatory junction potentials (mEJPs) with intracellular microelectrodes.
200 Since the muscle 6/7 NMJ is innervated by 1b and 1s boutons, mEJPs usually result from the
201 release of neurotransmitter vesicles from both types of boutons (Newman et al., 2017). Our
202 recordings revealed that mEJPs occurred more frequently but were smaller in *OK371>mbn*
203 larvae (Fig. 4A-B). The decrease in amplitude was not secondary to a change in the electrical
204 properties of the muscle as there was no difference in input resistance (*OK371/+*, 3.37 ± 0.69
205 $\text{M}\Omega$, $n = 8$; *OK371>mbn* = $3.99 \pm 0.99 \text{ M}\Omega$, $n = 8$, $P = 0.613$) or resting potential (*OK371/+*,
206 $-69.6 \pm 1.48 \text{ mV}$, $n = 8$; *OK371>mbn*, $-67.6 \pm 1.55 \text{ mV}$, $n = 8$, $P = 0.365$). Although we did not
207 directly investigate the source of the more frequent smaller mEJPs, the notion that they are
208 due to the observed selective increase in the number of 1b boutons is suggested by the fact
209 that 1b-dependent mEJPs are smaller than 1s-dependent mEJPs (Newman et al., 2017). In
210 parallel with the changes in spontaneous synaptic events, there was a small (~11 %) decrease
211 in the mean amplitude of electrically-evoked excitatory junction potentials (EJPs) caused by
212 single stimuli applied to the nerve at a low frequency (0.1 Hz) (Fig. 4C). There was no
213 difference between EJPs in mean rise time (*OK371/+*, $2.67 \pm 0.178 \text{ ms}$, $n = 8$; *OK371>mbn*,
214 $3.23 \pm 0.33 \text{ ms}$, $n = 8$, $P = 0.728$) or mean time constant of decay (*OK371/+*, $44.9 \pm 3.1 \text{ ms}$, n
215 = 8; *OK371>mbn*, $36.6 \pm 4.6 \text{ ms}$, $n = 8$, $P = 0.154$). The relatively small fall in EJP amplitude
216 is likely to reflect the smaller size of the 1b-dependent component of the EJP relative to that
217 of the 1s-dependent component (Newman et al., 2017).

218

219 **Overexpression of *mnb* in motor neurons slowed recovery from frequency-dependent**
220 **depression at the larval NMJ**

221 To investigate the effects of neuronal *mnb* overexpression on recycling of synaptic vesicles
222 during electrically-evoked transmitter release, EJPs were evoked with pairs of electrical stimuli
223 separated by intervals of varying duration (10 ms – 10 s) or with repeated trains of 10 stimuli
224 applied at a high frequency (10 Hz, a frequency 100 times higher than that at which the single
225 EJPs were evoked) (Kauwe and Isacoff, 2013). At control NMJs, paired pulses separated by
226 intervals shorter than 200 ms caused depression of the amplitude of the second EJP relative
227 to that of the first and the depression was stronger for shorter inter-stimulus intervals (Fig. 5A).
228 The dependence of paired-pulse depression on interval duration was unaltered in
229 *OK371>mnb* larvae (Fig. 5A), indicating that *mnb* overexpression did not alter release from a
230 readily releasable pool of vesicles (Regehr, 2012). When transmitter release was evoked at
231 control NMJs with a train of 10 stimuli at 10 Hz, there was rapid depression of the EJP
232 amplitude by ~20% within the first 3 events (Fig. 5B). In the one-minute interval before the
233 next train, the EJP amplitude recovered fully so that the amplitude of the first EJP in the second
234 train was the same as in the first train (Fig. 5B). This ability to recover did not wane during the
235 recording; the amplitude of the first EJP in each train did not differ between 8 trains (Fig. 5B).
236 These effects are consistent with previous studies (Kauwe and Isacoff, 2013) and confirm
237 rapid depletion and replenishment of the readily releasable pool of vesicles (Regehr, 2012).
238 However, the same pattern of nerve stimulation produced different effects at *OK371>mnb*
239 NMJs (Fig. 5B). The percentage decrease in EJP amplitude during each train was the same
240 as at control NMJs, but the depression was not fully reversed during the intervals between
241 trains, so that the first EJP in each train was smaller than the first EJP in the preceding train.
242 The depression in amplitude accumulated over the 8 trains, resulting in an overall fall of 10%.
243 To confirm that the changes in EJP amplitude were due to presynaptic changes in transmitter
244 release and were not postsynaptically mediated by a decrease in the unitary depolarisations
245 comprising each EJP, we measured the amplitudes of 200 mEJPs immediately before and

246 200 mEJPs immediately after the series of trains at each NMJ. At both control and
247 *OK371>mnb* NMJs, the cumulative distribution of mEJP amplitudes before and after a series
248 of trains was similar; although they were not identical, the observed slight increase in the
249 number of larger mEJPs cannot explain the decline in EJP amplitude (Fig. 5C). These results
250 show that *mnb* overexpression slowed replenishment of the readily releasable pool of vesicles,
251 an effect consistent with the reported slowing of endocytosis of transmitter vesicles by
252 *DYRK1A* overexpression (Kim et al., 2010).

253

254

255 **Discussion**

256 This study demonstrated that neuronal overexpression of *mnb*, the *Drosophila* ortholog of
257 DYRK1A, is sufficient to induce motor impairment, accelerate age-related decline in motor
258 performance, shorten lifespan and cause age-dependent neurodegeneration. This study also
259 found that neuronal *mnb* overexpression at a glutamatergic synapse alters presynaptic
260 structure, modifies basal synaptic transmission and delays recovery from short-term synaptic
261 depression. This provides useful information about the gene's function and the pathological
262 effects of increased expression in a model system. However, it is important to note that this
263 does not represent a high-fidelity recapitulation of DS or the complexity of the human *DYRK1A*
264 locus, because *Gal4*-mediated overexpression of a specific isoform does not accurately
265 replicate the expression level or pattern caused by triplication of a whole genomic region of
266 human chromosome 21.

267

268 People with DS have impaired motor skills which are evident from childhood and are caused
269 by abnormal development of the nervous system (Malak et al., 2015; Stagni et al., 2018).
270 Later, in middle age, they undergo faster age-dependent motor decline, which is an early
271 marker of future dementia, comorbidities and mortality, and is likely caused by
272 histopathological changes in the brain (Anderson-Mooney et al., 2016; Buchman and Bennett,
273 2011). The life expectancy of people with DS is about 28 years shorter than the general
274 population (O'Leary et al., 2018). By taking advantage of the relatively short life cycle of
275 *Drosophila* and transgenic overexpression of *mnb* in neurons, we have demonstrated a
276 potential role for neuronal DYRK1A overexpression in the accelerated age-dependent decline
277 of motor function and shortening of life expectancy in DS. The genetic basis of these aspects
278 of DS are more difficult and costly to explore in mouse models of DS, due to the time required
279 to study aged mice. Our finding that *mnb* overexpression causes age-related
280 neurodegeneration confirms previous studies inferring a link between *DYRK1A*
281 overexpression and degeneration and loss of neurons (Duchon and Herault, 2016; García-
282 Cerro et al., 2017; Watson-Scales et al., 2018; Wegiel et al., 2008), which is associated with

283 faster age-related decline in motor and cognitive function in DS and AD-DS. Our results also
284 reinforce the conclusion from earlier studies with adult mice overexpressing *DYRK1A* or
285 *Dyrk1a*, alone or as part of a chromosomal segment, that triplication of *DYRK1A* is likely to
286 contribute to motor deficits in DS (Altafaj et al., 2001; Arque et al., 2013; Garcia-Cerro et al.,
287 2018; Martínez de Lagrán et al., 2004; Ortiz-Abalia et al., 2008; Souchet et al., 2014; Watson-
288 Scales et al., 2018).

289

290 In addition to the smaller brain size and fewer brain neurons in DS and mouse models of DS,
291 there are alterations in the structure of brain synapses that are predicted to modify synaptic
292 function (Contestabile et al., 2017; Dierssen, 2012; Stagni et al., 2018). A previous study
293 showed that *DYRK1A* overexpression in mice changes postsynaptic morphology in the cortex
294 and in cultured cortical neurons by reducing the number and length of dendrites and by
295 reducing the number of dendritic spines but elongating their shape (Martinez de Lagran et al.,
296 2012). It also decreased the number of synapses formed. Our study shows that *mnb*
297 overexpression changes presynaptic structure and that this happens in a neuron-specific
298 manner; *mnb* overexpression in the two glutamatergic motoneurons innervating the larval NMJ
299 increased the number of 1b boutons without changing the number of 1s boutons. These data
300 are consistent with a previous study which demonstrated that reduced levels of *mnb* caused
301 a decrease, and increased levels of the *mnb-F* transcript an increase, in the number of boutons
302 at the NMJ (Chen et al., 2014), but did not differentiate between 1b and 1s boutons.

303

304 The cognitive and motor deficits in DS arise from aberrant information processing in the brain
305 that is likely due, in part, to changes in synaptic transmission or synaptic plasticity. Individuals
306 with DS have impaired synaptic plasticity in the motor cortex (Battaglia et al., 2008). Our
307 finding that *mnb* overexpression slows replenishment of the readily releasable pool of vesicles,
308 and also modifies basal synaptic transmission, confirms a previous suggestion that *DYRK1A*
309 overexpression contributes to synaptic dysfunction and cognitive deficits associated with DS,
310 made on the basis of the observed slowing of endocytosis of transmitter vesicles in cultured

311 mouse hippocampal neurons overexpressing human *DYRK1A* (Kim et al., 2010). The effects
312 of *DYRK1A* on synaptic function may be splice variant specific as we found that
313 overexpression of the *mnb-H* transcript caused a decrease in mEJP and EJP amplitude,
314 whereas overexpression of *mnb-F* in a previous study did not alter mEJP or EJP amplitude
315 at the larval NMJ (Chen et al., 2014).

316

317 The effects of neuronal *mnb* overexpression on larval NMJ function replicate some, but not
318 all, the documented changes in glutamatergic synaptic transmission in the brain of mouse
319 models of DS. These include a decrease in the amplitude of spontaneous excitatory
320 postsynaptic currents (sEPSCs) in neocortical neurons of Ts65Dn mice (Cramer et al., 2015),
321 compromised glutamate release in response to stimuli trains at hippocampal CA1 synapses
322 of Ts1Cje mice (Siarey et al., 2005) and a decrease in EPSC amplitude in hippocampal CA3
323 neurons of Ts65Dn mice (Hanson et al., 2007). However, in contrast to the increase in mEJP
324 frequency caused by *mnb* overexpression at the larval NMJ, electrophysiological studies have
325 found a decrease in the frequency of mEPSCs in hippocampal CA3 neurons of Ts65Dn mice,
326 sEPSCs in neocortical neurons of Ts65Dn mice and sEPSCs in neurons derived from trisomy
327 21 induced pluripotent stem cells, or no change in mEPSC frequency in the prefrontal cortex
328 of TgDyrk1a mice or mossy fibre-CA3 synapses in Tc1 mice (Contestabile et al., 2017).

329

330 Our study further elucidates the effect of *DYRK1A* overexpression in a model system, giving
331 insight into the contribution of increased dosage to various DS phenotypes. It supports the
332 future development of pharmacological inhibitors of *DYRK1A* as treatments for multiple
333 aspects of DS and DS-AD (Duchon and Herault, 2016; Stringer et al., 2017). Further work is
334 necessary to fully understand interactions between *DYRK1A* and other triplicated Hsa21
335 genes in DS, in specific cell types and during defined periods of development and ageing.

336

337

338

339

340 **Materials and Methods**

341 ***Animals***

342 Flies were raised with a 12 h:12 h light dark cycle with lights on at ZT 0 (Zeitgeber time) on
343 standard *Drosophila* medium (0.7% agar, 1.0% soya flour, 8.0% polenta/maize, 1.8% yeast,
344 8.0% malt extract, 4.0% molasses, 0.8% propionic acid, 2.3% nipagen) at 25°C. Flies were
345 transferred to vials containing fresh medium twice weekly. The *OK371-Gal4* (Bloomington
346 stock center numbers: 26160), *Elav-Gal4* (87060), *GMR-Gal4* (9146) flies were obtained from
347 the Bloomington *Drosophila* Stock Centre. *Canton Special white-* (*CSw-*) flies were a gift from
348 Dr Scott Waddell (University of Oxford), *UAS-mnb* flies (*minibrain-H*, CG42273) were kindly
349 provided by Dr Kweon Yu (Korea Research Institute of Bioscience and Biotechnology), *EB1-*
350 *Gal4*; *UAS-mCD8-GFP* flies were donated by Dr Frank Hirth (Kings College London).

351

352 ***Behaviour***

353 *mnb* expression was driven throughout the nervous system using *Elav-Gal4* (Robinow and
354 White, 1991) for experiments investigating behaviour of wandering third instar larvae, the
355 number of boutons at the larval NMJ, and synaptic transmission at the larval NMJ. All
356 behavioural experiments took place at 25°C. Larval locomotor experiments were conducted
357 on a 9.5 cm petri dish containing 1.6% agarose. A single third instar wandering larva was
358 selected, washed in a drop of distilled H₂O, transferred to the agarose and allowed 30 s to
359 acclimatise. To analyse free movement, the dish was placed over a 0.5 cm grid and the
360 number of lines the larva crawled across in one minute was counted by eye. The self-righting
361 assay was conducted as described elsewhere (Lowe et al., 2018; Picao-Osorio et al., 2015);
362 the larva was gently rolled onto its back on the agarose using a fine moistened paintbrush,
363 held for one second and released, and the time for it to right itself was recorded.

364

365 The negative geotaxis assay was performed as described previously (Ali et al., 2011). A cohort
366 of 10 flies was transferred without anaesthesia to an empty 9.5 cm tube with a line drawn 2

367 cm from the top. After 1 minute acclimatisation, the vial was sharply tapped 3 times to knock
368 the flies to bottom. The number of flies to climb past the line within 10 s was recorded. 15
369 cohorts of 10 flies were tested for each genotype. Age-dependent changes in climbing were
370 assessed by repeating the negative geotaxis assay at 10, 20 and 30 days post-eclosure
371 (Gargano et al., 2005). For the survival assay, 10 cohorts of 10 once-mated females were
372 transferred to a vial of fresh food twice weekly and the number of surviving flies recorded at
373 each transfer.

374

375 ***Antibody staining and visualisation at the NMJ***

376 Wandering third instar larvae were dissected in ice-cold, Ca²⁺-free HL3.1-like solution (in mM:
377 70 NaCl, 5 KCl, 10 NaHCO₃, 115 sucrose, 5 trehalose, 5 HEPES, 10 MgCl₂) to produce a
378 larval “fillet” (Brent et al., 2009). The fillet was fixed for 30 minutes in 4% paraformaldehyde
379 (Sigma Labs), washed three times in 1% Triton-X (Sigma Labs) and blocked for one hour in
380 5% normal goat serum (Fitzgerald Industries) and 1% Triton-X at room temperature. It was
381 incubated overnight in 1/500 mouse FITC-conjugated anti-horseradish peroxidase (HRP-
382 FITC) (Jackson Immunoresearch Laboratories, 115-035-003) and 1/500 rabbit anti-Discs
383 large (Dlg) (Biocompare, ABIN1387516) primary antibody, then for two hours in 1/500
384 AlexaFluor 633-conjugated goat anti-mouse secondary antibody (ThermoFisher Scientific, A-
385 21052) at room temperature. Each fillet was washed and mounted on a coverslip in
386 Vectashield (Vector Laboratories). Z-series of NMJs were imaged on a Leica SP5-II confocal
387 laser-scanning microscope using an oil immersion 40 × objective. The number of boutons at
388 the NMJ of muscle 6/7 in segment A2 was counted manually. ImageJ (rsb.info.nih.gov/ij/) was
389 used to manually outline muscle 6 and hence calculate their area.

390

391 ***Neurotoxicity***

392 Overexpression of *mnb* was driven in the eye using the *Glass multimer reporter (GMR-Gal4)*.
393 Images of the whole head of 1-2 day old flies were taken via a Zeiss AxioCam MRm camera
394 attached to a stereomicroscope (Zeiss SteREO Discovery.V8, up to 8× magnification), and

395 the surface area of the eye was calculated by manually outlining the eye in ImageJ
396 (rsb.info.nih.gov/ij/). Overexpression of *mnb* in GFP-tagged ellipsoid body (EB) ring neurons
397 was achieved by crossing *EB1-Gal4; UAS-mCD8-GFP* flies with *UAS-mnb* flies. Following
398 published methods (Williamson and Hiesinger, 2010), adult brains were dissected, fixed for
399 30 minutes in 4% paraformaldehyde and mounted on a coverslip in Vectashield (Vector
400 Laboratories). Slides were imaged on a Leica SP5-II confocal laser scanning microscope
401 using an oil immersion 40 × objective. A Z-stack of 25 images at 1 μm increments was
402 captured and combined into a 3-D projection using ImageJ (rsb.info.nih.gov/ij/); analysis was
403 performed by scrolling through all 25 images and counting the number of cells in one brain
404 hemisphere.

405

406 ***Electrophysiology***

407 Wandering third instar larvae were dissected as for antibody staining. The motor nerves were
408 severed just below the ventral ganglion and the brain was removed. CaCl₂ (1 mM) was added
409 to the bath solution for intracellular recording from muscle 6 of abdominal segments 2-4. Most
410 recordings were made in the presence of thapsigargin (2 μM), which minimises contraction
411 and hence facilitates intracellular recording, without affecting amplitudes of mEJPs or EJPs
412 (Guerrero et al., 2005; Newman et al., 2017). Sharp microelectrodes (thick-walled borosilicate
413 capillaries, pulled on a Sutter Flaming/Brown P-97 micropipette puller) were filled with 3M KCl
414 and had resistances of 20-30 MΩ. For recording of stimulus evoked excitatory junction
415 potentials (EJPs), severed nerves were drawn into a thin-walled glass-stimulating pipette and
416 stimulated with square-wave voltage pulses (0.1 ms, 10 V, A-M Systems Model 2100 Isolated
417 Pulse Simulator), 10 times at 0.1 Hz. EJPs and spontaneously-occurring miniature EJPs
418 (mEJPs) were recorded at a controlled room temperature of 22-25°C with a Geneclamp 500
419 amplifier (Axon Instruments) and were further amplified with a LHBF-48x amplifier (NPI
420 Electronic). The membrane potential was allowed to stabilise for one minute, the initial value
421 was recorded, and then set to -70 mV by injecting current with the Geneclamp 500 amplifier.

422 The muscle input resistance was measured by injecting current using the Axon Geneclamp
423 500, to bring the membrane potential to -100, -80, -60 and -40 mV, and subtracting the
424 electrode resistance from the slope of the resulting voltage/current graph. Voltage signals
425 were low-pass filtered at 1.67 kHz (10 kHz 4 pole Bessel on Geneclamp 500, 1.7 kHz 8-pole
426 Bessel on LHBF-48x) and digitised at 25 kHz by a CED-1401 plus A/D interface (Cambridge
427 Electronic Design, UK) using Spike2 software (v. 5.13) (CED, Cambridge, UK). Recordings
428 were discarded if the initial resting membrane potential was more positive than -60 mV or
429 varied by more than 10% throughout the recording. Synaptic potentials were analysed off line
430 using Strathclyde Electrophysiology Software WinEDR (v3.5.2) and GraphPad Prism (v.6). All
431 synaptic events were verified manually.

432

433 Amplitudes and intervals of mEJPs were compared by creating a cumulative distribution for
434 each genotype of 1600 measurements across 8 animals, with each animal contributing 200
435 values. To analyse the mEJP waveform, a mean mEJP was constructed for each recording
436 from events showing a single clear peak and a smooth decay, so as to prevent distortion of
437 the waveform by closely occurring mEJPs. A single exponential was fitted to the decay of the
438 mean mEJP and the 10-90% rise-time was measured. Time zero for the exponential fit was
439 set to the time at the peak of the mEJP. EJPs were analysed by forming a mean of 10 events,
440 measuring the 10-90% rise-time of the mean event, and fitting the decay with the sum of three
441 exponentials (time zero was set at the time of the peak). A mean weighted time constant of
442 decay was calculated as $A_1 \cdot \tau_1 + A_2 \cdot \tau_2 + A_3 \cdot \tau_3$, where A_1 , A_2 and A_3 are the fractional amplitudes
443 of the three components, and τ_1 , τ_2 and τ_3 are their time constants.

444

445 For paired pulse analysis, two EJPs were evoked, separated with intervals varying in duration
446 between 0.01 and 10 s. The amplitude of the second event was calculated as a fraction of the
447 amplitude of the first. Pairs of stimuli were separated by 30 s. For high-frequency stimulation,
448 trains of 10 events evoked at 10 Hz were repeated 8 times at 1 min intervals. The amplitude

449 of each event was expressed as a fraction of a baseline value, defined as the mean amplitude
450 of 10 single EJPs evoked at 0.1 Hz. To compare mEJP amplitude before and after the trains,
451 200 mEJP amplitudes were measured immediately before the first train, and another 200
452 immediately after the eighth train. The measured values were pooled from 8 NMJs for each
453 genotype and cumulative amplitude distributions compared.

454

455 ***Statistical analysis***

456 Statistical analysis was conducted in GraphPad Prism (v. 6, La Jolla, CA). Data were tested
457 for normality using the Kolmogorov-Smirnov test; where appropriate means were compared
458 using Student's unpaired *t*-test, or medians were compared using a Mann-Whitney *U* test.
459 EJPs evoked by pairs or trains of stimuli were compared using repeated measures 2-way
460 ANOVA. Cumulative distributions were compared with a Kolmogorov-Smirnov test. Survival
461 curves were compared with a Mantel-Cox test. Data are given as median or mean \pm SEM. *n*
462 is given per genotype. An α level of $P < 0.05$ was considered significant.

463

464

465

466

468 **References**

- 469 Ahmed, M.M., Block, A., Tong, S., Davisson, M.T., and Gardiner, K.J. (2017). Age
470 exacerbates abnormal protein expression in a mouse model of Down syndrome. *Neurobiol*
471 *Aging* 57, 120-132.
- 472 Ahn, K.J., Jeong, H.K., Choi, H.S., Ryoo, S.R., Kim, Y.J., Goo, J.S., Choi, S.Y., Han, J.S.,
473 Ha, I., and Song, W.J. (2006). DYRK1A BAC transgenic mice show altered synaptic
474 plasticity with learning and memory defects. *Neurobiol Dis* 22, 463-472.
- 475 Ali, Y.O., Escala, W., Ruan, K., and Zhai, R.G. (2011). Assaying locomotor, learning, and
476 memory deficits in *Drosophila* models of neurodegeneration. *J Vis Exp*.
- 477 Altafaj, X., Dierssen, M., Baamonde, C., Martí, E., Visa, J., Guimerà, J., Oset, M., González,
478 J.R., Flórez, J., Fillat, C., *et al.* (2001). Neurodevelopmental delay, motor abnormalities and
479 cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of
480 Down's syndrome. *Hum Mol Genet* 10, 1915-1923.
- 481 Altafaj, X., Martin, E.D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrin, C., Dierssen, M., and
482 Fillat, C. (2013). Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates
483 hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. *Neurobiol*
484 *Dis* 52, 117-127.
- 485 Anderson-Mooney, A.J., Schmitt, F.A., Head, E., Lott, I.T., and Heilman, K.M. (2016). Gait
486 dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and
487 proposed mechanisms. *Brain Cogn* 104, 48-57.
- 488 Arque, G., Casanovas, A., and Dierssen, M. (2013). Dyrk1A is dynamically expressed on
489 subsets of motor neurons and in the neuromuscular junction: possible role in Down
490 syndrome. *PLoS One* 8, e54285.
- 491 Atwood, H.L., Karunanithi, S., Georgiou, J., and Charlton, M.P. (1997). Strength of synaptic
492 transmission at neuromuscular junctions of crustaceans and insects in relation to calcium
493 entry. *Invert Neurosci* 3, 81-87.
- 494 Battaglia, F., Quartarone, A., Rizzo, V., Ghilardi, M.F., Di Rocco, A., Tortorella, G., and
495 Girlanda, P. (2008). Early impairment of synaptic plasticity in patients with Down's
496 syndrome. *Neurobiol Aging* 29, 1272-1275.
- 497 Brent, J.R., Werner, K.M., and McCabe, B.D. (2009). *Drosophila* larval NMJ dissection. *J Vis*
498 *Exp*.
- 499 Buchman, A.S., and Bennett, D.A. (2011). Loss of motor function in preclinical Alzheimer's
500 disease. *Expert Rev Neurother* 11, 665-676.
- 501 Bykhovskaia, M., and Vasin, A. (2017). Electrophysiological analysis of synaptic
502 transmission in *Drosophila*. *Wiley Interdiscip Rev Dev Biol*.
- 503 Chen, C.K., Bregere, C., Paluch, J., Lu, J.F., Dickman, D.K., and Chang, K.T. (2014).
504 Activity-dependent facilitation of Synaptojanin and synaptic vesicle recycling by the Minibrain
505 kinase. *Nat Commun* 5, 4246.
- 506 Contestabile, A., Magara, S., and Cancedda, L. (2017). The GABAergic Hypothesis for
507 Cognitive Disabilities in Down Syndrome. *Front Cell Neurosci* 11, 54.
- 508 Cramer, N.P., Xu, X., T, F.H., and Galdzicki, Z. (2015). Altered intrinsic and network
509 properties of neocortical neurons in the Ts65Dn mouse model of Down syndrome. *Physiol*
510 *Rep* 3.
- 511 Creau, N., Cabet, E., Daubigny, F., Souchet, B., Bennai, S., and Delabar, J. (2016).
512 Specific age-related molecular alterations in the cerebellum of Down syndrome mouse
513 models. *Brain Res* 1646, 342-353.
- 514 Diaper, D.C., Adachi, Y., Sutcliffe, B., Humphrey, D.M., Elliott, C.J., Stepto, A., Ludlow, Z.N.,
515 Vanden Broeck, L., Callaerts, P., Dermaut, B., *et al.* (2013). Loss and gain of *Drosophila*
516 TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration
517 by loss-of-function phenotypes. *Hum Mol Genet* 22, 1539-1557.
- 518 Dierssen, M. (2012). Down syndrome: the brain in trisomic mode. In *Nat Rev Neurosci*
519 (England), pp. 844-858.

520 Duchon, A., and Herault, Y. (2016). DYRK1A, a Dosage-Sensitive Gene Involved in
521 Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome. *Front*
522 *Behav Neurosci* 10, 104.

523 Ellis, M.C., O'Neill, E.M., and Rubin, G.M. (1993). Expression of Drosophila glass protein
524 and evidence for negative regulation of its activity in non-neuronal cells by another DNA-
525 binding protein. *Development* 119, 855-865.

526 García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N.,
527 Arbonés, M.L., and Martínez-Cué, C. (2014). Overexpression of Dyrk1A is implicated in
528 several cognitive, electrophysiological and neuromorphological alterations found in a mouse
529 model of Down syndrome. *PLoS One* 9, e106572.

530 García-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., and Martínez-Cué, C. (2017).
531 Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues
532 several Alzheimer's disease phenotypes. *Neurobiol Dis* 106, 76-88.

533 Garcia-Cerro, S., Vidal, V., Lantigua, S., Berciano, M.T., Lafarga, M., Ramos-Cabrer, P.,
534 Padro, D., Rueda, N., and Martinez-Cue, C. (2018). Cerebellar alterations in a model of
535 Down syndrome: The role of the Dyrk1A gene. *Neurobiol Dis* 110, 206-217.

536 Gargano, J.W., Martin, I., Bhandari, P., and Grotewiel, M.S. (2005). Rapid iterative negative
537 geotaxis (RING): a new method for assessing age-related locomotor decline in Drosophila.
538 *Exp Gerontol* 40, 386-395.

539 Gramates, L.S., Marygold, S.J., Santos, G.D., Urbano, J.M., Antonazzo, G., Matthews, B.B.,
540 Rey, A.J., Tabone, C.J., Crosby, M.A., Emmert, D.B., *et al.* (2017). FlyBase at 25: looking to
541 the future. *Nucleic Acids Res* 45, D663-D671.

542 Guerrero, G., Reiff, D.F., Agarwal, G., Ball, R.W., Borst, A., Goodman, C.S., and Isacoff,
543 E.Y. (2005). Heterogeneity in synaptic transmission along a Drosophila larval motor axon.
544 *Nat Neurosci* 8, 1188-1196.

545 Hanson, J.E., Blank, M., Valenzuela, R.A., Garner, C.C., and Madison, D.V. (2007). The
546 functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse
547 model of Down's syndrome. *J Physiol* 579, 53-67.

548 Herault, Y., Delabar, J.M., Fisher, E.M.C., Tybulewicz, V.L.J., Yu, E., and Brault, V. (2017).
549 Rodent models in Down syndrome research: impact and future opportunities. *Dis Model*
550 *Mech* 10, 1165-1186.

551 Hong, S.H., Lee, K.S., Kwak, S.J., Kim, A.K., Bai, H., Jung, M.S., Kwon, O.Y., Song, W.J.,
552 Tatar, M., and Yu, K. (2012). Minibrain/Dyrk1a regulates food intake through the Sir2-FOXO-
553 sNPF/NPY pathway in Drosophila and mammals. *PLoS Genet* 8, e1002857.

554 Jin, N., Yin, X., Gu, J., Zhang, X., Shi, J., Qian, W., Ji, Y., Cao, M., Gu, X., Ding, F., *et al.*
555 (2015). Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated
556 Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN
557 ALZHEIMER DISEASE. *J Biol Chem* 290, 15219-15237.

558 Jones, M.A., and Grotewiel, M. (2011). Drosophila as a model for age-related impairment in
559 locomotor and other behaviors. *Exp Gerontol* 46, 320-325.

560 Kauwe, G., and Isacoff, E.Y. (2013). Rapid feedback regulation of synaptic efficacy during
561 high-frequency activity at the Drosophila larval neuromuscular junction. *Proc Natl Acad Sci U*
562 *S A* 110, 9142-9147.

563 Kay, L.J., Smulders-Srinivasan, T.K., and Soundararajan, M. (2016). Understanding the
564 Multifaceted Role of Human Down Syndrome Kinase DYRK1A. *Adv Protein Chem Struct*
565 *Biol* 105, 127-171.

566 Kelly, P.A., and Rahmani, Z. (2005). DYRK1A enhances the mitogen-activated protein
567 kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. *Mol Biol*
568 *Cell* 16, 3562-3573.

569 Kim, Y., Park, J., Song, W.J., and Chang, S. (2010). Overexpression of Dyrk1A causes the
570 defects in synaptic vesicle endocytosis. *Neurosignals* 18, 164-172.

571 Kohsaka, H., Guertin, P.A., and Nose, A. (2017). Neural Circuits Underlying Fly Larval
572 Locomotion. *Curr Pharm Des* 23, 1722-1733.

573 Lahey, T., Gorczyca, M., Jia, X.X., and Budnik, V. (1994). The Drosophila tumor suppressor
574 gene *dlg* is required for normal synaptic bouton structure. *Neuron* 13, 823-835.

575 Lenz, S., Karsten, P., Schulz, J.B., and Voigt, A. (2013). *Drosophila* as a screening tool to
576 study human neurodegenerative diseases. *J Neurochem* 127, 453-460.

577 Liu, F., Liang, Z., Wegiel, J., Hwang, Y.W., Iqbal, K., Grundke-Iqbal, I., Ramakrishna, N., and
578 Gong, C.X. (2008). Overexpression of Dyrk1A contributes to neurofibrillary degeneration in
579 Down syndrome. *FASEB J* 22, 3224-3233.

580 Lott, I.T., and Dierssen, M. (2010). Cognitive deficits and associated neurological
581 complications in individuals with Down's syndrome. *Lancet Neurol* 9, 623-633.

582 Lowe, S.A., Hodge, J.J.L., and Usowicz, M.M. (2018). A third copy of the Down syndrome
583 cell adhesion molecule (*Dscam*) causes synaptic and locomotor dysfunction in *Drosophila*.
584 *Neurobiol Dis* 110, 93-101.

585 Mahr, A., and Aberle, H. (2006). The expression pattern of the *Drosophila* vesicular
586 glutamate transporter: a marker protein for motoneurons and glutamatergic centers in the
587 brain. *Gene Expr Patterns* 6, 299-309.

588 Malak, R., Kostukow, A., Krawczyk-Wasielewska, A., Mojs, E., and Samborski, W. (2015).
589 Delays in Motor Development in Children with Down Syndrome. *Med Sci Monit* 21, 1904-
590 1910.

591 Martínez de Lagrán, M., Altafaj, X., Gallego, X., Martí, E., Estivill, X., Sahún, I., Fillat, C., and
592 Dierssen, M. (2004). Motor phenotypic alterations in *TgDyrk1a* transgenic mice implicate
593 *DYRK1A* in Down syndrome motor dysfunction. *Neurobiol Dis* 15, 132-142.

594 Martínez de Lagrán, M., Benavides-Piccione, R., Ballesteros-Yañez, I., Calvo, M., Morales,
595 M., Fillat, C., Defelipe, J., Ramakers, G.J., and Dierssen, M. (2012). *Dyrk1A* influences
596 neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical
597 neurons. *Cereb Cortex* 22, 2867-2877.

598 McGurk, L., Berson, A., and Bonini, N.M. (2015). *Drosophila* as an In Vivo Model for Human
599 Neurodegenerative Disease. *Genetics* 201, 377-402.

600 Murakami, N., Bolton, D.C., Kida, E., Xie, W., and Hwang, Y.W. (2012). Phosphorylation by
601 *Dyrk1A* of clathrin coated vesicle-associated proteins: identification of the substrate proteins
602 and the effects of phosphorylation. *PLoS One* 7, e34845.

603 Newman, Z.L., Hoagland, A., Aghi, K., Worden, K., Levy, S.L., Son, J.H., Lee, L.P., and
604 Isacoff, E.Y. (2017). Input-Specific Plasticity and Homeostasis at the *Drosophila* Larval
605 Neuromuscular Junction. *Neuron* 93, 1388-1404.e1310.

606 O'Leary, L., Hughes-McCormack, L., Dunn, K., and Cooper, S.A. (2018). Early death and
607 causes of death of people with Down syndrome: A systematic review. *J Appl Res Intellect*
608 *Disabil*.

609 Ortiz-Abalia, J., Sahún, I., Altafaj, X., Andreu, N., Estivill, X., Dierssen, M., and Fillat, C.
610 (2008). Targeting *Dyrk1A* with AAVshRNA attenuates motor alterations in *TgDyrk1A*, a
611 mouse model of Down syndrome. *Am J Hum Genet* 83, 479-488.

612 Picao-Osorio, J., Johnston, J., Landgraf, M., Berni, J., and Alonso, C.R. (2015). MicroRNA-
613 encoded behavior in *Drosophila*. *Science* 350, 815-820.

614 Regehr, W.G. (2012). Short-term presynaptic plasticity. *Cold Spring Harb Perspect Biol* 4,
615 a005702.

616 Robinow, S., and White, K. (1991). Characterization and spatial distribution of the ELAV
617 protein during *Drosophila melanogaster* development. *J Neurobiol* 22, 443-461.

618 Ruiz-Mejias, M., Martínez de Lagrán, M., Mattia, M., Castano-Prat, P., Perez-Mendez, L.,
619 Ciria-Suarez, L., Gener, T., Sancristobal, B., García-Ojalvo, J., Gruart, A., *et al.* (2016).
620 Overexpression of *Dyrk1A*, a Down Syndrome Candidate, Decreases Excitability and
621 Impairs Gamma Oscillations in the Prefrontal Cortex. *J Neurosci* 36, 3648-3659.

622 Shi, J., Zhang, T., Zhou, C., Chohan, M.O., Gu, X., Wegiel, J., Zhou, J., Hwang, Y.W., Iqbal,
623 K., Grundke-Iqbal, I., *et al.* (2008). Increased dosage of *Dyrk1A* alters alternative splicing
624 factor (ASF)-regulated alternative splicing of tau in Down syndrome. *J Biol Chem* 283,
625 28660-28669.

626 Siarey, R.J., Villar, A.J., Epstein, C.J., and Galdzicki, Z. (2005). Abnormal synaptic plasticity
627 in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. *Neuropharmacology*
628 49, 122-128.

629 Souchet, B., Guedj, F., Sahún, I., Duchon, A., Daubigney, F., Badel, A., Yanagawa, Y.,
630 Barallobre, M.J., Dierssen, M., Yu, E., *et al.* (2014). Excitation/inhibition balance and learning
631 are modified by Dyrk1a gene dosage. *Neurobiol Dis* 69, 65-75.
632 Stagni, F., Giacomini, A., Emili, M., Guidi, S., and Bartesaghi, R. (2018). Neurogenesis
633 impairment: An early developmental defect in Down syndrome. *Free Radic Biol Med* 114,
634 15-32.
635 Stringer, M., Goodlett, C.R., and Roper, R.J. (2017). Targeting trisomic treatments:
636 optimizing Dyrk1a inhibition to improve Down syndrome deficits. *Mol Genet Genomic Med* 5,
637 451-465.
638 Thomazeau, A., Lassalle, O., Iafrafi, J., Souchet, B., Guedj, F., Janel, N., Chavis, P.,
639 Delabar, J., and Manzoni, O.J. (2014). Prefrontal deficits in a murine model overexpressing
640 the down syndrome candidate gene *dyrk1a*. *J Neurosci* 34, 1138-1147.
641 von Groote-Bidlingmaier, F., Schmoll, D., Orth, H.M., Joost, H.G., Becker, W., and Barthel,
642 A. (2003). DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase
643 gene expression. *Biochem Biophys Res Commun* 300, 764-769.
644 Watson-Scales, S., Kalmar, B., Lana-Elola, E., Gibbins, D., La Russa, F., Wiseman, F.,
645 Williamson, M., Saccon, R., Slender, A., Olerinyova, A., *et al.* (2018). Analysis of motor
646 dysfunction in Down Syndrome reveals motor neuron degeneration. *PLoS Genet* 14,
647 e1007383.
648 Wegiel, J., Dowjat, K., Kaczmarek, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur
649 Kolecka, B., Silverman, W.P., Reisberg, B., Deleon, M., *et al.* (2008). The role of
650 overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down
651 syndrome. *Acta Neuropathol* 116, 391-407.
652 Wegiel, J., Kaczmarek, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.C., Yang, S.M.,
653 Frackowiak, J., Mazur-Kolecka, B., Silverman, W.P., *et al.* (2011). Link between DYRK1A
654 overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat
655 tau protein in Down syndrome. *J Neuropathol Exp Neurol* 70, 36-50.
656 Williamson, W.R., and Hiesinger, P.R. (2010). Preparation of developing and adult
657 *Drosophila* brains and retinae for live imaging. *J Vis Exp*.
658 Wiseman, F.K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V.L.,
659 Fisher, E.M., and Strydom, A. (2015). A genetic cause of Alzheimer disease: mechanistic
660 insights from Down syndrome. *Nat Rev Neurosci* 16, 564-574.
661 Woods, Y.L., Cohen, P., Becker, W., Jakes, R., Goedert, M., Wang, X., and Proud, C.G.
662 (2001). The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at
663 Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a
664 glycogen synthase kinase 3-priming kinase. *Biochem J* 355, 609-615.
665 Zerbino, D.R., Achuthan, P., Akanni, W., Amode, M.R., Barrell, D., Bhai, J., Billis, K.,
666 Cummins, C., Gall, A., Girón, C.G., *et al.* (2018). Ensembl 2018. *Nucleic Acids Res* 46,
667 D754-D761.
668 Zigman, W.B. (2013). Atypical aging in Down syndrome. *Dev Disabil Res Rev* 18, 51-67.

669

670 **Figure Legends**

671

672 **Figure 1. Motor deficits in larvae, accelerated age-dependent motor decline in adult**
673 **flies and shortened adult lifespan due to neuronal overexpression of *mnb***

674 (A) *Elav>mnb* larvae crossed fewer lines of a 0.5 cm grid in 60 s than control larvae (*Elav/+*,
675 14.7 ± 0.44 , $n = 15$; *Elav>mnb*, 12.1 ± 0.86 , $n = 15$; mean \pm SEM, $*P = 0.014$, Student's *t*-test),
676 and with greater variance ($F(14,14) = 3.768$, $P = 0.0184$, *F*-test). (B) *Elav>mnb* larvae took

677 longer than controls to perform a self-righting task (*Elav/+*, 5.5 ± 1.16 s, $n = 15$; *Elav>mnb*, 12
678 ± 2.56 s; $n = 15$; mean \pm SEM, $*P = 0.029$, Student's *t*-test) and with greater variance (F
679 $(14,14) = 4.802$, $P = 0.0059$, *F*-test). Each point in the plots (A, B) is from a different animal;
680 horizontal lines indicate mean values. (C) The age-dependent decline in climbing ability in a
681 negative geotaxis assay was steeper and showed greater variance for *Elav>mnb* adult flies
682 than for controls ($F(3,84) = 13.8$; $***P < 0.0001$, repeated measures two-way ANOVA, $n = 15$
683 groups of flies); at 1 day old there was no difference in the percentage of flies that climbed
684 successfully (*Elav/+*, 90.59 ± 1.82 %, $n = 15$; *Elav>mnb* $\pm 85.94 \pm 1.46$ %, $n = 15$; mean \pm
685 SEM, $P = 0.8262$, repeated measures two-way ANOVA and Sidak's multiple comparison).
686 Values plotted are mean \pm SEM, $n = 15$ groups of 10 flies for each genotype. (D) *Elav>mnb*
687 flies had a shorter lifespan relative to controls ($n = 100$ animals per genotype at day 0, $***P <$
688 0.0001 , log-rank (Mantel-Cox) test).

689

690 **Figure 2. Neurotoxicity and age-related neurodegeneration caused by *mnb***
691 **overexpression**

692 (A) (Left) Representative images of the eyes of control adult flies (*GMR/+*) and flies with *mnb*
693 overexpression driven in the eye by *GMR-Gal4* (*GMR>mnb*). (Right) The surface area of the
694 eyes in *GMR>mnb* flies was reduced (*GMR/+*, 0.14 ± 0.005 mm², $n = 10$; *GMR>mnb*, $0.09 \pm$
695 0.005 mm², $n = 10$; mean \pm SEM, $***P < 0.0001$, Student's *t*-test). Each point in the plot is from
696 a different animal, horizontal lines indicate means. (B) (Left) Representative images of clusters
697 of GFP-expressing ellipsoid body neurons in one brain hemisphere, with and without *mnb*
698 overexpression driven by *EB1-Gal4*, in 1 d and 40 d old flies. Calibration bar is 10 μ m. (Right)
699 The number of cells did not differ at 1 d (*EB1>mCD8-GFP*, 32.59 ± 0.48 , $n = 15$ (black);
700 *EB1>mCD8-GFP, mnb*; 31.47 ± 0.47 , $n = 15$ (grey); mean \pm SEM, $P = 0.757$, repeated
701 measures two-way ANOVA and Sidak's multiple comparison) but decreased between 1 and
702 40 d in *EB1>mCD8-GFP, mnb* flies; ($F(1,28) = 10.56$; $n = 15$; $P = 0.003$, repeated measures
703 two-way ANOVA). Values plotted are mean \pm SEM from 15 flies for each genotype.

704

705 **Figure 3. Overexpression of *mnb* in motor neurons increased the number of 1b boutons**

706 (A) Representative images of motor nerve endings at the NMJ of muscle 6/7 in the A2 segment
707 of *OK371/+* (top) and *OK371>mnb* (bottom) larvae. The neuronal membrane is labelled with
708 HRP (green); type 1b boutons but not type 1s boutons (arrowheads) are preferentially labelled
709 with Dlg (magenta). Scale bar is 25 μ m. (B) *OK371>mnb* NMJs had more 1b boutons
710 (*OK371/+*, 24.93 ± 1.11 , $n = 15$; *OK371>mnb*, 32.80 ± 1.52 , $n = 15$, mean \pm SEM, *** $P =$
711 0.0003, Student's *t*-test) but there was no difference in the number of 1s boutons (*OK371/+*,
712 32.6 ± 2.62 , $n = 15$; *OK371>mnb*, 38.6 ± 3.34 , $n = 15$, mean \pm SEM, $P = 0.169$, Student's *t*-
713 test). Each value plotted is from a different animal, horizontal lines indicate means.

714

715 **Figure 4. Overexpression of *mnb* in motor neurons altered basal synaptic transmission.**

716 (A) Representative voltage recordings (3 s traces) from NMJs of *OK371/+* (black) and
717 *OK371>mnb* (grey) larvae showing spontaneous mEJPs recorded at a membrane potential of
718 -70 mV. (B) Cumulative frequency distributions of mEJP amplitude (left) and inter-mEJP
719 interval (right) (1600 events, 200 from each of 8 NMJ recordings). *OK371>mnb* mEJPs were
720 smaller (** $P < 0.0001$) and more frequent (** $P < 0.0001$), Kolmogorov-Smirnov test. (C)
721 (Left) Representative image of a single electrically-evoked EJP at an *OK371/+* NMJ and an
722 *OK371>mnb* NMJ at a membrane potential of -70 mV. (Right) The median EJP amplitude
723 (horizontal line) was reduced in *OK371>mnb* NMJs (*OK371/+*, 51.26 mV, $n = 8$; *OK371>mnb*,
724 45.55 mV, $n = 8$; mean \pm SEM, * $P = 0.0281$). Each point plotted is from a different animal.

725


726 **Figure 5. *mnb* overexpression in motor neurons slowed recovery from frequency-**
727 **induced depression**

728 (A) (Left) Representative pairs of stimuli evoked EJPs at *OK371/+* (black) and *OK371>mnb*
729 (grey) NMJs. Dashed lines compare the first EJP (EJP₁) and dotted lines compare the second
730 EJP (EJP₂). (Right) Plots of paired-pulse ratio (EJP₂/EJP₁, mean \pm SEM, $n = 8$ for each
731 genotype) against inter-pulse interval reveal no difference in synaptic depression ($F(9, 126)$
732 = 0.1343; $n = 8$; $P = 0.9987$, repeated measures two-way ANOVA). (B) High-frequency

733 stimulation protocol. 10 EJPs were evoked at 0.1 Hz to establish a mean baseline amplitude
734 followed by 8 trains of 10 EJPs at 10 Hz, at one minute intervals. (*Left*) Representative traces
735 of train 1 (*upper*) and train 8 (*lower*) recorded from *OK371/+* and *OK371>mnb* NMJs. Dashed
736 lines compare EJP₁ in each train. (*Right*) Plots of EJP amplitude during trains 1 and 8,
737 expressed as a fraction of baseline amplitude (mean ± SEM, $n = 8$ for each genotype). During
738 the first train, the decline in EJP amplitude was unaffected by genotype ($F(1, 14) = 0.22$, $P =$
739 0.6486 , repeated measures two-way ANOVA). In the eighth train, EJPs were smaller at
740 *OK371>mnb* NMJs ($F(1, 14) = 4.98$, $P = 0.0426$) but the rate of decline during the 8th train was
741 not different ($F(9, 126) = 0.99$, $P = 0.4540$, repeated measures two-way ANOVA). (C)
742 Cumulative frequency distributions of mEJP amplitudes ($n = 1600$ from 8 NMJ recordings)
743 from immediately before (solid line) and immediately after (dashed line) the trains, for *OK371/+*
744 (*left*) and *OK371>mnb* (*right*) NMJs; after the trains, a minority of mEJPs were larger in both
745 *OK371/+* ($*P = 0.0117$) and *OK371>mnb* ($*P = 0.018$) NMJs (log-rank (Mantel-Cox) test).

746

747 **Fig. 1**



748


749

750

751

752

753 **Fig. 2**




754

755

756


757 **Fig. 3**



758


759

760 **Fig. 4**



761

762 **Fig. 5**



763

764

765

766

767

768

769

770